A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice

Brief description of study

This is a retrospective, multi-center observational cohort study. This study will be
implemented first in Germany (approximately 50 sites), the United Kingdom (approximately 20
sites) and Sweden (approximately 25 sites), followed by a selected number of countries in
Europe, depending on apremilast local availability. The design of this apremilast
retrospective study aims to provide clinical information regarding the treatment initiation
and outcomes in psoriasis patients when prescribed apremilast in real world settings. In
addition, this study is aiming at capturing physicians' and patients' treatment goals when
initiating apremilast and whether these goals are achieved following apremilast use. This
study is primarily descriptive in nature, and no a priori hypotheses are specified. Patients
must voluntarily sign an informed consent form, be 18 or over, have been diagnosed with
plaque psoriasis and have been treated with apremilast during the previous 5-7 months to
participate in this study. They must not be involved in any other clinical study involving
apremilast.